William T. Abraham, MD, Joins Cardiac Dimensions as Chief Medical Officer
3.9.2025 12:00:00 CEST | Business Wire | Press release
Prominent heart failure cardiologist Dr. William Abraham to play pivotal role in the advancement of the Carillon Mitral Contour System® to heart failure patients with FMR.
Cardiac Dimensions®, a leader in transcatheter therapies for heart failure, announced today the appointment of William T. Abraham, MD, as Chief Medical Officer. A globally recognized expert in heart failure and device-based therapies, Dr. Abraham will help lead the company’s clinical and regulatory strategies as it advances toward U.S. regulatory approval and continues to expand European commercial sales of the Carillon Mitral Contour System®.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903095354/en/
Dr. William T. Abraham, Chief Medical Officer at Cardiac Dimensions
Dr. Abraham most recently served as the Chief Medical Officer at V-Wave Ltd., where he led the U.S. pivotal trial and played a key role in advancing the company’s transcatheter interatrial shunt therapy, culminating in a significant heart failure-focused acquisition by Johnson & Johnson. Dr. Abraham is a College of Medicine Distinguished Professor at The Ohio State University, where he was the Director of the Division of Cardiovascular Medicine for more than 15 years, and has published over 650 peer-reviewed papers. He is internationally known for his leadership in advancing heart failure treatments, including cardiac resynchronization therapy, remote hemodynamic monitoring, and transcatheter valve repair. Dr. Abraham has also served as national or global principal investigator on more than 50 multicenter trials, including important trials within the mitral valve space.
“We are delighted to welcome Dr. Abraham to the Cardiac Dimensions leadership team,” said Rick Wypych, President and CEO of Cardiac Dimensions. “Bill’s impact on the heart failure field is unmatched. His input and influence on the Carillon therapy will help drive the success and adoption of this much-needed therapy. In addition, his experience with large-scale clinical trials and regulatory pathways will be instrumental to the completion of our pivotal U.S. landmark study – The EMPOWER Trial.”
“I’ve spent my career working to bring novel and impactful therapies to people living with heart failure,” said Dr. Abraham. “What drew me to Cardiac Dimensions is the Carillon therapy’s unique position in the heart failure treatment paradigm. It offers a physiologically elegant approach to reducing mitral regurgitation, preserving future treatment options, and modifying the disease process itself. I’m particularly encouraged by the consistent data showing favorable atrial and ventricular remodeling, symptom improvement, and a excellent safety profile – even in patients with proportionate MR who are often excluded from other therapies.”
The Carillon Mitral Contour System has received CE Mark and is available for sale in Europe and other countries that recognize CE Mark.
About the CarillonMitral Contour System®
The Carillon Mitral Contour System is a minimally invasive device designed to treat heart failure patients with functional mitral regurgitation by reshaping the mitral valve apparatus via the coronary sinus. It is commercially available in Europe, as well as other countries, and is currently being studied in the U.S. pivotal EMPOWER Trial.
About the EMPOWER Trial
The EMPOWER Trial is a prospective, randomized, sham-controlled pivotal study evaluating the safety and effectiveness of the Carillon Mitral Contour System® in heart failure patients with mild to severe functional mitral regurgitation. Designed to enroll up to 300 patients across leading U.S. and international centers, the trial aims to support FDA approval by demonstrating the Carillon therapy’s potential to improve symptoms, cardiac structure, and long-term outcomes in a broad heart failure population.
About Cardiac Dimensions®
Cardiac Dimensions is committed to addressing the rapidly growing patient population suffering from heart failure with functional mitral regurgitation. With decades of clinical experience and thousands of patients treated worldwide, the company’s Carillon device is uniquely positioned as a durable therapy designed to treat early and late-stage patients, improve symptoms and reverse disease progression. Learn more at www.cardiacdimensions.com.
CAUTION: In the United States, the Carillon System is an investigational device, limited by federal law to investigational use.
Cardiac Dimensions, Carillon, and Carillon Mitral Contour System are registered trademarks of Cardiac Dimensions.
© 2025 Cardiac Dimensions. All rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250903095354/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom